{"organizations": [], "uuid": "ac056b4fd4b11d11649954edd80f601da7a80590", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pfizer-granted-fda-breakthrough-th/brief-pfizer-granted-fda-breakthrough-therapy-designation-for-trumenba-idUSASC09WRW", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba速 (Meningococcal Group B Vaccine)", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T15:00:00.000+03:00", "replies_count": 0, "uuid": "ac056b4fd4b11d11649954edd80f601da7a80590"}, "author": "", "url": "https://www.reuters.com/article/brief-pfizer-granted-fda-breakthrough-th/brief-pfizer-granted-fda-breakthrough-therapy-designation-for-trumenba-idUSASC09WRW", "ord_in_thread": 0, "title": "BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba速 (Meningococcal Group B Vaccine)", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "meningococcal group b vaccine", "sentiment": "negative"}, {"name": "fda breakthrough therapy des", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "pfizer", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 23, 2018 / 12:00 PM / Updated 11 minutes ago BRIEF-Pfizer Granted FDA Breakthrough Therapy Designation For Trumenba速 (Meningococcal Group B Vaccine) Reuters Staff 1 Min Read \nApril 23 (Reuters) - Pfizer Inc: \n* PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR TRUMENBA速 (MENINGOCOCCAL GROUP B VACCINE) FOR THE PREVENTION OF INVASIVE MENINGOCOCCAL B DISEASE IN CHILDREN AGES 1 TO 9 YEARS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-23T15:00:00.000+03:00", "crawled": "2018-04-23T15:16:04.005+03:00", "highlightTitle": ""}